Medicare’s GLP-1 Bridge Starts July 1: $50 Copays, Three Drugs, and One Catch

The $50 monthly copay is the headline. The fact that it doesn’t count toward Medicare’s out-of-pocket cap is the part nobody’s talking about—and for some federal retirees, the math may not favor the switch.

Starting July 1, 2026, Medicare beneficiaries with obesity will be able to fill prescriptions for Wegovy, the Zepbound KwikPen, or Foundayo at a $50 monthly copay under a new program called the Medicare GLP-1 Bridge. The 18-month pilot, announced May 6 and detailed in updated CMS guidance this week, is the first time Medicare has covered weight-loss medications at scale—federal law has prohibited it for more than two decades. The $50 number is real. So is the fine print most headlines have skipped.

How the Medicare GLP-1 Bridge Works

The Bridge covers all formulations of Wegovy (semaglutide—both injectable and the recently approved oral pill), the KwikPen formulation of Zepbound (tirzepatide), and all formulations of Foundayo (orforglipron). To qualify, beneficiaries must be enrolled in a Medicare Part D plan or a Medicare Advantage prescription-drug plan, meet the obesity criteria set by their plan, and clear prior authorization.

The economics rest on a negotiated $245 monthly net price to Medicare, well below the $1,000-plus list prices Novo Nordisk and Eli Lilly charge cash-pay customers. Pharmacies are reimbursed at WAC minus the $50 copay, plus a dispensing fee and applicable sales tax. Humana, leveraging its LI NET infrastructure, has been designated the central processor.

Why This Is Historically Significant

Medicare has been statutorily barred from covering weight-loss medications since the Medicare Modernization Act of 2003. The bar was written into the original Part D legislation and has never been amended. The Bridge is the first programmatic carve-out that puts these drugs within reach of the roughly 65 million Americans on Medicare—including the demographic that arguably needs them most.

Recent post-hoc analyses presented at the European Congress on Obesity (ECO 2026) in Istanbul show that the 65-and-older population responds to these drugs nearly as well as younger adults:

• Semaglutide 2.4 mg produced a 15.4% mean weight loss at Week 68 in a 358-patient pooled analysis of adults 65 and older drawn from the STEP 1/3/4/5/8/9 trials.
• Orforglipron 36 mg produced a 13.0% mean weight loss at Week 72 in the ATTAIN-1 65+ subgroup (obesity without type 2 diabetes).
• Orforglipron 36 mg produced a 12.2% mean weight loss at Week 72 in the ATTAIN-2 65+ subgroup (obesity with type 2 diabetes).

Both datasets were released by Novo Nordisk and Eli Lilly the same weekend the Bridge was announced. The coordination is unlikely to be a coincidence.

The Federal-Retiree Catch

For most Medicare beneficiaries, a $50 monthly copay on a drug that lists at more than $1,000 is an unambiguous win. For approximately 4 million federal retirees with Federal Employees Health Benefits coverage that integrates with Medicare, the math is more complicated.

As Government Executive reported this month, some FEHB Part D plans already cover Wegovy at lower copays than the Bridge offers. Blue Cross Blue Shield Standard Part D, for example, charges $35 per month for Wegovy 0.25 mg—five dollars less than the Bridge.

The bigger issue is what doesn’t count. The $50 Bridge copay does not apply against the Part D deductible. It also does not count toward Medicare’s $2,100 annual out-of-pocket cap. A federal retiree paying $50 a month on the Bridge will end the year having spent $600 that didn’t move them any closer to their out-of-pocket ceiling. The same retiree using a standard FEHB Part D plan, even at a higher monthly copay, may reach the cap sooner and pay less out of pocket over the calendar year.

Federal retirees should not assume the Bridge is automatically the cheaper option. Compare your existing FEHB formulary copays against the Bridge before switching plans.

What This Means for Compounding

The Bridge will put further downward pressure on demand for compounded GLP-1s. For two years, the primary reason patients turned to compounded semaglutide and tirzepatide was cost—list prices were prohibitive and most insurance didn’t cover the branded drugs. With Medicare now offering branded versions at $50 monthly to a 65-million-person population, the financial gap collapses for the older demographic that has driven a substantial share of compounding demand.

The broader 503A and 503B regulatory landscape remains in flux. Several peptides were moved off FDA Category 2 in April. The Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24 will likely set the next milestone for federal policy. But the demand-side question—why would a Medicare beneficiary pay a compounding pharmacy when their plan covers the FDA-approved version at $50?—has a clear answer for the first time.

What to Watch

The Bridge runs through December 31, 2027. CMS has not announced what happens after that date—whether the program will be extended, expanded, or sunset. Permanent statutory coverage of weight-loss drugs in Medicare would require an act of Congress to amend the 2003 prohibition.

For now, the practical takeaways:

• If you’re on Medicare and your physician agrees a GLP-1 is appropriate for you, the Bridge is likely to be the cheapest legitimate path starting July 1.
• If you have FEHB plus Medicare, compare your formulary numbers before switching. The Bridge copay does not count toward your Part D out-of-pocket cap, and that math matters.
• Prior authorization remains a gate. The Bridge does not remove it.
• Foundayo is the only oral option in the program. Zepbound coverage is limited to the KwikPen formulation, not the standard auto-injector.
• The Bridge is a pilot, not permanent. Build a longer-term plan with your physician that doesn’t assume $50 access after 2027.

Peptidings will update this story as CMS releases additional implementation guidance and as Week 6 and 7 Foundayo launch data clarifies the trajectory of oral GLP-1 demand under insurance coverage.